Active substance
Dicloxacillin
- US FDA 9
- US price lines 2
- WHO EML 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DICLOXACILLIN SODIUM | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | CHARTWELL RX | Prescription | 3 Jun 1982 |
| DICLOXACILLIN SODIUM | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | AUROBINDO PHARMA | Prescription | 23 Sep 2022 |
| PATHOCIL | EQ 62.5MG BASE/5ML | for suspension · oral | WYETH AYERST | Discontinued | 22 Apr 1968 |
| PATHOCIL | EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule · oral | WYETH AYERST | Discontinued | 9 May 1968 |
| DICLOXACILLIN SODIUM | EQ 250MG BASE; EQ 125MG BASE; EQ 500MG BASE | capsule · oral | CHARTWELL RX | Discontinued | 1 Apr 1971 |
| DICLOXACILLIN SODIUM | EQ 62.5MG BASE/5ML | for suspension · oral | APOTHECON | Discontinued | 1 Apr 1971 |
| DYCILL | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | GLAXOSMITHKLINE | Discontinued | 31 Dec 1979 |
| DYCILL | EQ 250MG BASE; EQ 500MG BASE | capsule · oral | GLAXOSMITHKLINE | Discontinued | |
| DYNAPEN | EQ 62.5MG BASE/5ML | for suspension · oral | APOTHECON | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DICLOXACILLIN 250 MG CAPSULE | $0.59036 | per EA | 23 Sep 2026 |
| US NADAC | DICLOXACILLIN 500 MG CAPSULE | $0.92742 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Therapeutic equivalent to cloxacillin for Bacterial infection of joint; First choice: Therapeutic equivalent to cloxacillin for Osteomyelitis or osteitis; First choice: Therapeutic equivalent to cloxacillin for Bacterial cellulitis, erysipelas or lymphangitis; Second choice: Therapeutic equivalent to cloxacillin for Sepsis without septic shock
Safety signals and safety-related labeling changes
- EMA PRAC 14 Apr 2016 PRAC signal: Metabolic acidosis following administration of flucloxacillin in association with paracetamol
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.